NEWARK, Calif. --(BUSINESS WIRE)--Nov. 12, 2019-- Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company pioneering new innovations in neuromodulators for aesthetic and therapeutic indications, today announced that the company will participate in the Stifel 2019 Healthcare Conference,

NEWARK, Calif. --(BUSINESS WIRE)--Nov. 6, 2019-- Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company pioneering new innovations in neuromodulators for aesthetic and therapeutic indications, today announced that the company will participate in the Credit Suisse 28th Annual Healthcare

– Conference call and webcast today at 4:30 p.m. ET – NEWARK, Calif. --(BUSINESS WIRE)--Nov. 4, 2019-- Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company pioneering new innovations in neuromodulators for aesthetic and therapeutic indications, today reported financial results for the

- DaxibotulinumtoxinA for Injection (DAXI) has potential to be first long-acting neuromodulator for treatment of this debilitating involuntary muscle movement disorder - - Topline data expected in second half of 2020 - NEWARK, Calif. --(BUSINESS WIRE)--Nov. 4, 2019-- Revance Therapeutics, Inc.

- Results show DaxibotulinumtoxinA for Injection (DAXI) can reduce frown lines for 24 weeks (approximately 6 months) or more - NEWARK, Calif. --(BUSINESS WIRE)--Nov. 4, 2019-- Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company pioneering new innovations in neuromodulators for

Conference Call Scheduled for Monday, November 4, 2019 at 4:30 p.m. ET NEWARK, Calif. --(BUSINESS WIRE)--Oct. 28, 2019-- Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company pioneering new innovations in neuromodulators for aesthetic and therapeutic indications, today announced that

- Revance’s long-acting neuromodulator DAXI will be featured in three abstracts and three oral presentations at the American Society for Dermatologic Surgery (ASDS) 2019 Annual Meeting in Chicago - NEWARK, Calif. --(BUSINESS WIRE)--Oct. 23, 2019-- Revance Therapeutics, Inc.

- Mark Foley to lead company as it gears up to commercialize next-generation neuromodulator – - Change in leadership unrelated to company performance - - Revance on track to submit BLA for DAXI for the treatment of glabellar lines in the Fall of 2019, as previously announced - NEWARK, Calif.

  NEWARK, Calif. --(BUSINESS WIRE)--Oct. 2, 2019-- Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company pioneering new innovations in neuromodulators for aesthetic and therapeutic indications, today announced the company is certified as a great workplace by the independent analysts at

  NEWARK, Calif. --(BUSINESS WIRE)--Sep. 25, 2019-- Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company pioneering new innovations in neuromodulators for aesthetic and therapeutic indications, today announced that the company will participate in the 2019 Cantor Global Healthcare